Cardiol Therapeutics Inc. (CRDL) Stock Forecast
CRDL analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.67 / 5 from 6 analysts
- Price target
- $8.49 average of analyst targets
- Upside to target
- +672.2% from the latest close
- Next earnings
- November 12, 2026 EPS estimate $-0.05
- 52-week range
- $0.93 – $2.29
CRDL analyst ratings
6 analystsNumber of analysts at each rating.
CRDL price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CRDL earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.08 | −$0.08 | −$0.07 | −$0.12 | +36.4% | 3 |
| Current fiscal year (2026) | −$0.32 | −$0.33 | −$0.29 | −$0.39 | +18.6% | 3 |
| Next fiscal year (2027) | −$0.33 | −$0.42 | −$0.22 | −$0.32 | −3.0% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CRDL revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 4 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 6 |
| Next fiscal year (2027) | $1.7M | $0 | $10.0M | 0.0% | 6 |
CRDL EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CRDL revenue: reported and forecast
CRDL EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.10 | −$0.08 | −$0.08 | −$0.08 | −$0.08 | −26.1% | 1 up · 0 down |
| Current fiscal year (2026) | −$0.36 | −$0.36 | −$0.33 | −$0.31 | −$0.32 | −11.9% | 0 up · 1 down |
| Next fiscal year (2027) | −$0.28 | −$0.28 | −$0.30 | −$0.33 | −$0.33 | +16.7% | 1 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CRDL earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CRDL beat in 9 of 12.
What analysts expect from CRDL
6 analysts cover Cardiol Therapeutics; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $8.49, 672.2% above the latest close of $1.10. Analysts expect earnings of −$0.32 per share for 2026, +18.6% from a year earlier. For 2027 the average estimate is −$0.33 per share on revenue of $1.7 million. Cardiol Therapeutics beat the EPS estimate in 9 of the last 12 quarters.
Related: CRDL income statement, CRDL key metrics, CRDL chart. See the CRDL stock overview for the latest quote and news.
CRDL forecast FAQ
What is Cardiol Therapeutics's price target?
The average analyst price target for Cardiol Therapeutics is $8.49, 672.2% above the latest close of $1.10.
Is Cardiol Therapeutics a buy, hold or sell?
Of 6 analysts covering Cardiol Therapeutics, 4 rate it a strong buy, 2 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Cardiol Therapeutics's EPS forecast?
Analysts forecast −$0.32 per share for 2026 (range −$0.33 to −$0.29); for 2027 the estimate is −$0.33.
When does Cardiol Therapeutics report earnings?
Cardiol Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 12, 2026 after the market closes; the EPS estimate is $-0.05.
Does Cardiol Therapeutics usually beat earnings estimates?
Cardiol Therapeutics reported EPS at or above the analyst estimate in 9 of the last 12 quarters.